Almirall Acquires Exclusive Worldwide Rights to Develop and Market Novo Nordisk's NN-8828 Monoclonal Antibody for Dermatological Inflammatory Diseases
Portfolio Pulse from Charles Gross
Almirall has acquired exclusive worldwide rights to develop and market Novo Nordisk's NN-8828 monoclonal antibody for dermatological inflammatory diseases. Novo Nordisk will receive an upfront payment, additional development and commercial milestone payments, and tiered royalties based on future global sales.
February 19, 2024 | 3:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novo Nordisk will benefit financially from the deal with Almirall through an upfront payment, milestone payments, and royalties on future sales of NN-8828.
The agreement with Almirall provides Novo Nordisk with immediate financial benefits from the upfront payment and potential long-term revenue through milestone payments and sales royalties. This deal could positively impact NVO's financial outlook and investor sentiment in the short term, especially if NN-8828 progresses successfully through development and commercialization.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 90